[The immunological activity of the bacterial strain Escherichia coli M17 used in preparing a commercial preparation of colibacterin]. / Immunologicheskaia aktivnost' bakterii shtamma Escherichia coli M17, ispol'zuemogo pri izgotovlenii kommercheskogo preparata kolibakterina.

The toxicity, immunogenic properties and protective activity of the live culture of E. coli M17 and antigenic preparations obtained from cell suspensions of this strain have been studied under experimental conditions. As revealed in experiments on mice, E. coli M17 live culture has low virulence, moderate toxicity and provides the protection of immunized mice from challenge with homologous and highly virulent E. coli strains. E. coli M17 live culture, when introduced orally or intravenously into rabbits, ensures the synthesis of 02 and H6 antibodies. Blood sera taken from immunized rabbits yield better results than initial sera in experiments on the passive protection of mice. The results of our experiments show the expediency of the clinical trials of Colibacterin as a perspective Escherichia live oral vaccine.

[Preventive properties of the blood sera from persons vaccinated with a Proteus vaccine made from soluble antigen complexes]. / Preventivnye svoistva syvorotok krovi liudei, vaktsinirovannykh proteinoi vaktsinoi iz rastvorimykh antigennykh kompleksov.

In experiments of the passive protection of mice the protective properties of sera obtained from humans before and after their immunization with Proteus vaccine used as a monopreparation or in combination with staphylococcal toxoid and/or pyoimmunogen were studied. When introduced in a single subcutaneous injection, Proteus vaccine prepared from soluble antigenic complexes ensured an increase in the protective properties of sera. The second injection of the vaccine essentially enhanced the protective potency of the sera of the immunized donors. The therapeutic injection of Proteus vaccine ensured the essential increase of the protective properties of the sera. This increase could be experimentally detected within at least 25-30 days from the beginning of immunization. The immunization of volunteers with Proteus vaccine in combination with pyoimmunogen and adsorbed staphylococcal toxoid ensured the maximum increase of the protective properties of their sera.

[Biological characteristics of 3 new substrains of laboratory mice used in evaluating the quality of pertussis vaccines]. / Biologicheskie kharakteristiki trekh novykh sublinii laboratornykh myshei, ispol'zuemykh pri otsenki kachestva kokliushnykh vaktsin.

NFR/NM, NFS/NM inbred mice and M : CFLP random bred mice have been shown to possess immunobiological properties making them suitable for the evaluation of the quality of pertussis vaccines and for their standardization. NFS/NM mice are highly sensitive to the histamine-sensitizing factor, while M : CFLP mice are sensitive to the lienotoxic factor of pertussis vaccines. All these substrains of mice have sufficient fertility for their breeding under the conditions of a commercial breeding establishment.

[Vaccine from soluble antigens for the specific therapy of Proteus infection]. / Vaktsina iz rastvorimykh abtigenov dlia spetsificheskoi terapii proteinoi infektsii.

A vaccine prepared from Proteus soluble antigens obtained by the disintegration of microbial cells with hydroxylamine is proposed. In animal experiments the vaccine has proved to be nontoxic when injected in large single doses or in smaller doses over a prolonged period and capable of protecting mice and rabbits from Proteus infection. No pronounced postvaccinal complications have been registered in humans immunized with the vaccine. The possibility of using the vaccine for immunizing donors with the aim of obtaining hyperimmune anti-Proteus plasma and for the active vaccinal therapy of patients with Proteus infection has been shown.